Nilofer Azad

Last updated
Nilofer Saba Azad
Alma mater Baylor College of Medicine
Scientific career
FieldsOncology
Institutions Johns Hopkins University

Nilofer Saba Azad is an American oncologist and physician-scientist specialized in the development of novel therapies for gastrointestinal cancers. She is a professor at the Johns Hopkins School of Medicine and a member of the Sidney Kimmel Comprehensive Cancer Center (SKCCC), where she directs several clinical research programs.

Contents

Education and Career

Azad earned a M.D. at Baylor College of Medicine in 2001. She completed a residency in internal medicine at Baylor in 2004, followed by a fellowship in medical oncology and hematology at the National Cancer Institute (NCI) in 2008. [1] After completing her training, Dr. Azad joined the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins School of Medicine, where she is currently a professor of oncology. She serves as co-director of the Developmental Therapeutics Clinical Research Program and the Cancer Genetic and Epigenetic Core Research Program at SKCCC. [2]

Research

Azad’s research centers on the clinical development of new treatments for gastrointestinal malignancies, including colorectal, pancreatic, and biliary tract cancers. She leads and participates in early-phase clinical trials investigating epigenetic therapy, [3] immunotherapies, [4] and other targeted approaches. Her work includes studies of KRAS-directed immunotherapy in collaboration with Dr. Elizabeth Jaffee. [5]

Honors

Azad is a member of the Stand Up To Cancer (SU2C) Epigenetics Dream Team and a Principal Investigator on the SU2C Colon Cancer Dream Team. She has held leadership roles in national and international cancer research organizations and has served on scientific advisory boards and review committees. [2]

In September 2021, Azad was appointed by U.S. president Joe Biden to serve on the NCI National Cancer Advisory Board, which provides guidance to the National Cancer Institute. [6] [2]

References

  1. ↑ "Nilofer Saba Azad, M.D., Professor of Oncology". Johns Hopkins Medicine. Retrieved 2021-09-22.
  2. 1 2 3 PD-icon.svg This article incorporates text from this source, which is in the public domain : "President Biden Appoints Members to National Cancer Advisory Board". The White House. 2021-09-15. Retrieved 2021-09-22.
  3. ↑ Azad, Nilofer; Zahnow, Cynthia A.; Rudin, Charles M.; Baylin, Stephen B. (May 2013). "The future of epigenetic therapy in solid tumours--lessons from the past". Nature Reviews. Clinical Oncology. 10 (5): 256–266. doi:10.1038/nrclinonc.2013.42. ISSN   1759-4782. PMC   3730253 . PMID   23546521.
  4. ↑ Le, Dung T.; Uram, Jennifer N.; Wang, Hao; Bartlett, Bjarne R.; Kemberling, Holly; Eyring, Aleksandra D.; Skora, Andrew D.; Luber, Brandon S.; Azad, Nilofer S.; Laheru, Dan; Biedrzycki, Barbara; Donehower, Ross C.; Zaheer, Atif; Fisher, George A.; Crocenzi, Todd S. (2015-06-25). "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency". New England Journal of Medicine. 372 (26): 2509–2520. doi:10.1056/NEJMoa1500596. ISSN   0028-4793. PMC   4481136 .
  5. ↑ Haldar, Saurav Daniel; Heumann, Thatcher Ross; Berg, Maureen; Ferguson, Anna; Lim, Su Jin; Wang, Hao; Nauroth, Julie; Laheru, Dan; Jaffee, Elizabeth M.; Azad, Nilofer Saba; Zaidi, Neeha (February 2023). "A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer" . Journal of Clinical Oncology. 41 (4_suppl): TPS814 –TPS814. doi:10.1200/JCO.2023.41.4_suppl.TPS814. ISSN   0732-183X.
  6. ↑ "Two Johns Hopkins scientists named to National Cancer Advisory Board". The Hub. Johns Hopkins University. 2021-09-16. Retrieved 2021-09-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.